CYTH vs. INAB, DYAI, OKYO, QNCX, SABS, ESLA, ACHL, TARA, INKT, and SRZN
Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include IN8bio (INAB), Dyadic International (DYAI), OKYO Pharma (OKYO), Quince Therapeutics (QNCX), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), MiNK Therapeutics (INKT), and Surrozen (SRZN). These companies are all part of the "biological products, except diagnostic" industry.
IN8bio (NASDAQ:INAB) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.
IN8bio received 13 more outperform votes than Cyclo Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Cyclo Therapeutics an outperform vote while only 68.97% of users gave IN8bio an outperform vote.
In the previous week, IN8bio had 13 more articles in the media than Cyclo Therapeutics. MarketBeat recorded 15 mentions for IN8bio and 2 mentions for Cyclo Therapeutics. IN8bio's average media sentiment score of 1.44 beat Cyclo Therapeutics' score of 0.13 indicating that Cyclo Therapeutics is being referred to more favorably in the news media.
92.1% of IN8bio shares are held by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are held by institutional investors. 33.0% of IN8bio shares are held by company insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
IN8bio has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.
IN8bio has a net margin of 0.00% compared to IN8bio's net margin of -1,864.03%. Cyclo Therapeutics' return on equity of -151.40% beat IN8bio's return on equity.
Cyclo Therapeutics has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.
IN8bio presently has a consensus target price of $10.00, indicating a potential upside of 792.86%. Cyclo Therapeutics has a consensus target price of $3.20, indicating a potential upside of 128.57%. Given Cyclo Therapeutics' higher probable upside, equities analysts plainly believe IN8bio is more favorable than Cyclo Therapeutics.
Summary
IN8bio beats Cyclo Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Cyclo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclo Therapeutics Competitors List
Related Companies and Tools
